EN DE
STOCK COMPARISON

Merck KGaA vs Neuland Laboratories: Fair Value & Quality

Both stocks run through our valuation models. Here is how Merck KGaA (MRK) and Neuland Laboratories (NEULANDLAB) compare, as of Oct 2, 2026.

As of Oct 2, 2026, Fair Value Calculator sees Merck KGaA as the less overvalued of the two: Merck KGaA trades at €134 versus a fair value of €109 (−19.0%), while Neuland Laboratories trades at ₹21,505 versus ₹5,987 (−72.2%).
Merck KGaA
MRK.XETRA · EUR · Health Care
−19.0%
upside to fair value
overvalued
Price€134
Fair Value€109
Quality62/100
Neuland Laboratories
NEULANDLAB.NSE · INR · Health Care
−72.2%
upside to fair value
overvalued
Price₹21,505
Fair Value₹5,987
Quality55/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Merck KGaANeuland Laboratories
Valuation
24.6×P/E (TTM)55.3×
15.1×Forward P/E43.8×
25.0×Median P/E at FY-end (10 FY, reported earnings)34.4×
2.77×P/S (TTM)11.63×
2.04×P/B14.72×
11.8×EV/EBITDA36.3×
2.15×PEGn/a
−19.0%Fair value upside−72.2%
1.6%Dividend yield0.1%
€2.20Dividend per sharen/a
Profitability
13.9%Operating margin30.6%
1.07×EBIT margin trend (5Y)2.01×
8.1%Return on equity15.9%
4.7%Return on assets7.2%
Growth
3.4%Revenue growth (YoY)119.2%
-1.7%Avg. growth/yr (3Y)20.3%
3.8%Avg. growth/yr (5Y)17.1%
+7.2%Value creation/yr+41.8%
Balance & size
15.5×Interest coverage (EBIT/interest)20.2×
0.36×Debt / equity0.09×
$66BMarket cap$3B
mixedGrowth qualityexpensive
Merck KGaA, median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 25. Neuland Laboratories, median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 34.4.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Neuland Laboratories leads: 7 to 8 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Merck KGaAof which business quality 61 · market factors 64 Neuland Laboratoriesof which business quality 54 · market factors 81
ProfitabilityMargins and returns on capital today
41
62
Quality GrowthAre margins and returns improving?
40
56
CashflowEarnings quality: real cash, not paper profit
57
24
Fin. StrengthBalance sheet, leverage, solvency risk
75
87
InvestmentDisciplined investing over empire-building
80
1
Low VolatilityCalm price path (market factor)
75
75
MomentumPrice trend over the last 3–12 months (market factor)
57
85
52W MomentumDistance to the 52-week high (market factor)
62
80
Net IssuanceShare count: buybacks or dilution?
82
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyMerck KGaAPrice €134Neuland LaboratoriesPrice ₹21,505
DCF Models−20.3%below the price€107−92.7%below the price₹1,567
Earnings-Based−60.4%below the price€53.25−81.9%below the price₹3,895
Dividend Discount−69.7%below the price€40.71−99.1%below the price₹196
Multiples−12.1%close to the price€118−74.1%below the price₹5,562
Asset-Based−67.2%below the price€44.06−95.4%below the price₹979
Growth DCF−29.7%below the price€94.57n/a
Economic Profit−50.6%below the price€66.44−84.7%below the price₹3,281
Growth Earnings−14.3%close to the price€115−72.2%below the price₹5,987
Minimum−69.7%below the price€40.71−99.1%below the price₹196
Maximum−12.1%close to the price€118−72.2%below the price₹5,987
Median−40.1%below the price€80.50−84.7%below the price₹3,281
Geometric mean−45.1%below the price€73.75−90.7%below the price₹2,000

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Merck KGaA: 23 of 26 models see the stock below the current price.

Neuland Laboratories: 17 of 17 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Merck KGaA
Price €134
Fair Value €109
Bear €60.04Bull €150
Neuland Laboratories
Price ₹21,505
Fair Value ₹5,987
Bear ₹4,191Bull ₹7,783

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Merck KGaA · Health Care

Quality score62 · above median
Fair value upside−19.0% · above median

Neuland Laboratories · Health Care

Quality score55 · above median
Fair value upside−72.2% · bottom 25%

Bottom line

As of Oct 2, 2026, Fair Value Calculator sees Merck KGaA as the less overvalued of the two: Merck KGaA trades at €134 versus a fair value of €109 (−19.0%), while Neuland Laboratories trades at ₹21,505 versus ₹5,987 (−72.2%).

Merck KGaA has the higher quality score (62/100).

Open Merck KGaA live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.